Peng Zhan

List of Publications by Year in Descending Order

146 papers	3,908 citations	35 h-index	55 g-index
159 ext. papers	4,805 ext. citations	6.4 avg, IF	5.71 L-index

#	Paper	IF	Citations
146	Contemporary Medicinal Chemistry Strategies for the Discovery and Development of Novel HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors.. *Journal of Medicinal Chemistry*, **2022**,	8.3	6
145	Novel RNase H inhibitors blocking RNA-directed strand displacement DNA synthesis by HIV-1 reverse transcriptase.. *Journal of Molecular Biology*, **2022**, 167507	6.5	0
144	Chemical space exploration around indolylarylsulfone scaffold led to a novel class of highly active HIV-1 NNRTIs with spiro structural features. *European Journal of Medicinal Chemistry*, **2022**, 238, 114471	6.8	0
143	Indolylarylsulfones bearing phenylboronic acid and phenylboronate ester functionalities as potent HIV-1 non-nucleoside reverse transcriptase inhibitors. *Bioorganic and Medicinal Chemistry*, **2021**, 53, 116531	3.4	2
142	Identification of novel potent HIV-1 inhibitors by exploiting the tolerant regions of the NNRTIs binding pocket. *European Journal of Medicinal Chemistry*, **2021**, 214, 113204	6.8	2
141	2,4,5-Trisubstituted Pyrimidines as Potent HIV-1 NNRTIs: Rational Design, Synthesis, Activity Evaluation, and Crystallographic Studies. *Journal of Medicinal Chemistry*, **2021**, 64, 4239-4256	8.3	11
140	The development of an effective synthetic route of rilpivirine. *BMC Chemistry*, **2021**, 15, 22	3.7	4
139	SARS-CoV-2 Entry inhibitors targeting virus-ACE2 or virus-TMPRSS2 interactions. *Current Medicinal Chemistry*, **2021**,	4.3	1
138	Design, synthesis and anti-HIV evaluation of novel 5-substituted diarylpyrimidine derivatives as potent HIV-1 NNRTIs. *Bioorganic and Medicinal Chemistry*, **2021**, 40, 116195	3.4	2
137	Exploiting the hydrophobic channel of the NNIBP: Discovery of novel diarylpyrimidines as HIV-1 NNRTIs against wild-type and K103N mutant viruses. *Bioorganic and Medicinal Chemistry*, **2021**, 42, 116239	3.4	1
136	Design, synthesis, and biological evaluation of piperidinyl-substituted [1,2,4]triazolo[1,5-a]pyrimidine derivatives as potential anti-HIV-1 agents with reduced cytotoxicity. *Chemical Biology and Drug Design*, **2021**, 97, 67-76	2.9	5
135	Design, synthesis, and evaluation of "dual-site"-binding diarylpyrimidines targeting both NNIBP and the NNRTI adjacent site of the HIV-1 reverse transcriptase. *European Journal of Medicinal Chemistry*, **2021**, 211, 113063	6.8	5
134	Discovery of highly potent and selective influenza virus neuraminidase inhibitors targeting 150-cavity. *European Journal of Medicinal Chemistry*, **2021**, 212, 113097	6.8	3
133	Exploiting the tolerant region I of the non-nucleoside reverse transcriptase inhibitor (NNRTI) binding pocket. Part 2: Discovery of diarylpyrimidine derivatives as potent HIV-1 NNRTIs with high Fsp values and favorable drug-like properties. *European Journal of Medicinal Chemistry*, **2021**, 213, 113051	6.8	4
132	Punicalagin is a neuraminidase inhibitor of influenza viruses. *Journal of Medical Virology*, **2021**, 93, 3465-3472	19.7	7
131	Recent developments in the medicinal chemistry of single boron atom-containing compounds. *Acta Pharmaceutica Sinica B*, **2021**, 11, 3035-3059	15.5	28
130	Medicinal chemistry strategies for discovering antivirals effective against drug-resistant viruses. *Chemical Society Reviews*, **2021**, 50, 4514-4540	58.5	30

129	HIV-1 and HBV RNase H as Metal-Chelating Inhibitors: Discovery and Medicinal Chemistry Strategies **2021**, 585-602		
128	Boronic acid-containing diarylpyrimidine derivatives as novel HIV-1 NNRTIs: Design, synthesis and biological evaluation. *Chinese Chemical Letters*, **2021**,	8.1	4
127	Discovery of Novel Dihydrothiopyrano[4,3-]pyrimidine Derivatives as Potent HIV-1 NNRTIs with Significantly Reduced hERG Inhibitory Activity and Improved Resistance Profiles. *Journal of Medicinal Chemistry*, **2021**, 64, 13658-13675	8.3	2
126	Medicinal chemistry strategies towards the development of effective SARS-CoV-2 inhibitors. *Acta Pharmaceutica Sinica B*, **2021**,	15.5	5
125	Structure-Based Design and Discovery of Pyridyl-Bearing Fused Bicyclic HIV-1 Inhibitors: Synthesis, Biological Characterization, and Molecular Modeling Studies. *Journal of Medicinal Chemistry*, **2021**, 64, 13604-13621	8.3	1
124	Discovery of potent and selective Cdc25 phosphatase inhibitors via rapid assembly and in situ screening of Quinonoid-focused libraries. *Bioorganic Chemistry*, **2021**, 115, 105254	5.1	2
123	Design, synthesis, and antiviral activity of phenylalanine derivatives as HIV-1 capsid inhibitors. *Bioorganic and Medicinal Chemistry*, **2021**, 48, 116414	3.4	0
122	Design, synthesis, and antiviral evaluation of novel piperidine-substituted arylpyrimidines as HIV-1 NNRTIs by exploring the hydrophobic channel of NNIBP. *Bioorganic Chemistry*, **2021**, 116, 105353	5.1	1
121	Discovery, optimization, and target identification of novel coumarin derivatives as HIV-1 reverse transcriptase-associated ribonuclease H inhibitors. *European Journal of Medicinal Chemistry*, **2021**, 225, 113769	6.8	3
120	Discovery of potential dual-target prodrugs of HIV-1 reverse transcriptase and nucleocapsid protein 7. *Bioorganic and Medicinal Chemistry Letters*, **2020**, 30, 127287	2.9	
119	Recent Developments in Small Molecular HIV-1 and Hepatitis B Virus RNase H Inhibitors **2020**, 273-292		
118	Inhibitors of SARS-CoV-2 Entry: Current and Future Opportunities. *Journal of Medicinal Chemistry*, **2020**, 63, 12256-12274	8.3	111
117	Targeting the entry step of SARS-CoV-2: a promising therapeutic approach. *Signal Transduction and Targeted Therapy*, **2020**, 5, 98	21	13
116	New techniques and strategies in drug discovery. *Chinese Chemical Letters*, **2020**, 31, 1695-1708	8.1	45
115	In situ click chemistry-based rapid discovery of novel HIV-1 NNRTIs by exploiting the hydrophobic channel and tolerant regions of NNIBP. *European Journal of Medicinal Chemistry*, **2020**, 193, 112237	6.8	11
114	Structure-Activity Relationship Exploration of NNIBP Tolerant Region I Leads to Potent HIV-1 NNRTIs. *ACS Infectious Diseases*, **2020**, 6, 2225-2234	5.5	8
113	Discovery of novel "Dual-site" binding oseltamivir derivatives as potent influenza virus neuraminidase inhibitors. *European Journal of Medicinal Chemistry*, **2020**, 191, 112147	6.8	5
112	Discovery and Characterization of Fluorine-Substituted Diarylpyrimidine Derivatives as Novel HIV-1 NNRTIs with Highly Improved Resistance Profiles and Low Activity for the hERG Ion Channel. *Journal of Medicinal Chemistry*, **2020**, 63, 1298-1312	8.3	20

111	Medicinal chemistry insights into novel CDC25 inhibitors. *European Journal of Medicinal Chemistry*, **2020**, 201, 112374	6.8	11
110	Structure-Based Bioisosterism Yields HIV-1 NNRTIs with Improved Drug-Resistance Profiles and Favorable Pharmacokinetic Properties. *Journal of Medicinal Chemistry*, **2020**, 63, 4837-4848	8.3	20
109	Discovery of novel 1,2,3-triazole oseltamivir derivatives as potent influenza neuraminidase inhibitors targeting the 430-cavity. *European Journal of Medicinal Chemistry*, **2020**, 187, 111940	6.8	12
108	Targeting dual tolerant regions of binding pocket: Discovery of novel morpholine-substituted diarylpyrimidines as potent HIV-1 NNRTIs with significantly improved water solubility. *European Journal of Medicinal Chemistry*, **2020**, 206, 112811	6.8	3
107	Fsp: A new parameter for drug-likeness. *Drug Discovery Today*, **2020**, 25, 1839-1845	8.8	52
106	Discovery and optimization of benzenesulfonamides-based hepatitis B virus capsid modulators via contemporary medicinal chemistry strategies. *European Journal of Medicinal Chemistry*, **2020**, 206, 112714	6.8	8
105	Novel Human Urate Transporter 1 Inhibitors as Hypouricemic Drug Candidates with Favorable Druggability. *Journal of Medicinal Chemistry*, **2020**, 63, 10829-10854	8.3	8
104	Exploring the hydrophobic channel of NNIBP leads to the discovery of novel piperidine-substituted thiophene[3,2-]pyrimidine derivatives as potent HIV-1 NNRTIs. *Acta Pharmaceutica Sinica B*, **2020**, 10, 878-894	15.5	26
103	Identification of highly potent and selective Cdc25 protein phosphatases inhibitors from miniaturization click-chemistry-based combinatorial libraries. *European Journal of Medicinal Chemistry*, **2019**, 183, 111696	6.8	11
102	Exploiting the Tolerant Region I of the Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Binding Pocket: Discovery of Potent Diarylpyrimidine-Typed HIV-1 NNRTIs against Wild-Type and E138K Mutant Virus with Significantly Improved Water Solubility and Favorable Safety Profiles. *Journal of Medicinal Chemistry*, **2019**, 62, 2083-2098	8.3	47
101	Design, synthesis and biological evaluation of "Multi-Site"-binding influenza virus neuraminidase inhibitors. *European Journal of Medicinal Chemistry*, **2019**, 178, 64-80	6.8	18
100	Contemporary medicinal-chemistry strategies for discovery of blood coagulation factor Xa inhibitors. *Expert Opinion on Drug Discovery*, **2019**, 14, 915-931	6.2	6
99	Molecular design opportunities presented by solvent-exposed regions of target proteins. *Medicinal Research Reviews*, **2019**, 39, 2194-2238	14.4	16
98	Overview of Recent Strategic Advances in Medicinal Chemistry. *Journal of Medicinal Chemistry*, **2019**, 62, 9375-9414	8.3	53
97	Resurrecting the Condemned: Identification of N-Benzoxaborole Benzofuran GSK8175 as a Clinical Candidate with Reduced Metabolic Liability. *Journal of Medicinal Chemistry*, **2019**, 62, 3251-3253	8.3	7
96	Designing influenza polymerase acidic endonuclease inhibitors via Privileged scaffoldR re-evolution/refining strategy. *Future Medicinal Chemistry*, **2019**,	4.1	8
95	Discovery of novel indolylarylsulfones as potent HIV-1 NNRTIs via structure-guided scaffold morphing. *European Journal of Medicinal Chemistry*, **2019**, 182, 111619	6.8	7
94	Design, synthesis and biological evaluation of 3-hydroxyquinazoline-2,4(1H,3H)-diones as dual inhibitors of HIV-1 reverse transcriptase-associated RNase H and integrase. *Bioorganic and Medicinal Chemistry*, **2019**, 27, 3836-3845	3.4	7

93	Discovery of piperidine-substituted thiazolo[5,4-d]pyrimidine derivatives as potent and orally bioavailable HIV-1 non-nucleoside reverse transcriptase inhibitors. *Communications Chemistry*, **2019**, 2,	6.3	15
92	Novel urate transporter 1 (URAT1) inhibitors: a review of recent patent literature (2016-2019). *Expert Opinion on Therapeutic Patents*, **2019**, 29, 871-879	6.8	20
91	Targeting the hydrophobic channel of NNIBP: discovery of novel 1,2,3-triazole-derived diarylpyrimidines as novel HIV-1 NNRTIs with high potency against wild-type and K103N mutant virus. *Organic and Biomolecular Chemistry*, **2019**, 17, 3202-3217	3.9	28
90	Discovery of novel 1,4-disubstituted 1,2,3-triazole phenylalanine derivatives as HIV-1 capsid inhibitors. *RSC Advances*, **2019**, 9, 28961-28986	3.7	24
89	Design, synthesis, and biologic evaluation of novel galloyl derivatives as HIV-1 RNase H inhibitors. *Chemical Biology and Drug Design*, **2019**, 93, 582-589	2.9	8
88	Design, synthesis and biological evaluation of novel acetamide-substituted doravirine and its prodrugs as potent HIV-1 NNRTIs. *Bioorganic and Medicinal Chemistry*, **2019**, 27, 447-456	3.4	12
87	Contemporary medicinal-chemistry strategies for the discovery of selective butyrylcholinesterase inhibitors. *Drug Discovery Today*, **2019**, 24, 629-635	8.8	24
86	Identification of Dihydrofuro[3,4- d]pyrimidine Derivatives as Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors with Promising Antiviral Activities and Desirable Physicochemical Properties. *Journal of Medicinal Chemistry*, **2019**, 62, 1484-1501	8.3	41
85	Discovery of potent HIV-1 non-nucleoside reverse transcriptase inhibitors by exploring the structure-activity relationship of solvent-exposed regions I. *Chemical Biology and Drug Design*, **2019**, 93, 430-437	2.9	8
84	Efficient drug discovery by rational lead hybridization based on crystallographic overlay. *Drug Discovery Today*, **2019**, 24, 805-813	8.8	15
83	The Journey of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) from Lab to Clinic. *Journal of Medicinal Chemistry*, **2019**, 62, 4851-4883	8.3	74
82	First discovery of a potential carbonate prodrug of NNRTI drug candidate RDEA427 with submicromolar inhibitory activity against HIV-1 K103N/Y181C double mutant strain. *Bioorganic and Medicinal Chemistry Letters*, **2018**, 28, 1348-1351	2.9	8
81	Discovery of Novel Diarylpyrimidine Derivatives as Potent HIV-1 NNRTIs Targeting the "NNRTI Adjacent" Binding Site. *ACS Medicinal Chemistry Letters*, **2018**, 9, 334-338	4.3	25
80	Further Exploring Solvent-Exposed Tolerant Regions of Allosteric Binding Pocket for Novel HIV-1 NNRTIs Discovery. *ACS Medicinal Chemistry Letters*, **2018**, 9, 370-375	4.3	21
79	Discovery of C-1 modified oseltamivir derivatives as potent influenza neuraminidase inhibitors. *European Journal of Medicinal Chemistry*, **2018**, 146, 220-231	6.8	21
78	Current insights into anti-HIV drug discovery and development: a review of recent patent literature (2014-2017). *Expert Opinion on Therapeutic Patents*, **2018**, 28, 299-316	6.8	27
77	Discovery of novel diarylpyrimidines as potent HIV-1 NNRTIs by investigating the chemical space of a less explored "hydrophobic channel". *Organic and Biomolecular Chemistry*, **2018**, 16, 1014-1028	3.9	18
76	Targeting the entrance channel of NNIBP: Discovery of diarylnicotinamide 1,4-disubstituted 1,2,3-triazoles as novel HIV-1 NNRTIs with high potency against wild-type and E138K mutant virus. *European Journal of Medicinal Chemistry*, **2018**, 151, 339-350	6.8	44

75	Design, synthesis, and antiviral evaluation of novel hydrazone-substituted thiophene[3,2-d]pyrimidine derivatives as potent human immunodeficiency virus-1 inhibitors. *Chemical Biology and Drug Design*, **2018**, 92, 2009-2021	2.9	8
74	5-Hydroxypyrido[2,3-b]pyrazin-6(5H)-one derivatives as novel dual inhibitors of HIV-1 reverse transcriptase-associated ribonuclease H and integrase. *European Journal of Medicinal Chemistry*, **2018**, 155, 714-724	6.8	21
73	Update on Recent Developments in Small Molecular HIV-1 RNase H Inhibitors (2013-2016): Opportunities and Challenges. *Current Medicinal Chemistry*, **2018**, 25, 1682-1702	4.3	30
72	Design, synthesis and biological evaluation of tacrine-1,2,3-triazole derivatives as potent cholinesterase inhibitors. *MedChemComm*, **2018**, 9, 149-159	5	39
71	Development of a practical synthesis of etravirine via a microwave-promoted amination. *Chemistry Central Journal*, **2018**, 12, 144		1
70	Structure-Based Optimization of N-Substituted Oseltamivir Derivatives as Potent Anti-Influenza A Virus Agents with Significantly Improved Potency against Oseltamivir-Resistant N1-H274Y Variant. *Journal of Medicinal Chemistry*, **2018**, 61, 9976-9999	8.3	24
69	Structural basis for potent and broad inhibition of HIV-1 RT by thiophene[3,2-]pyrimidine non-nucleoside inhibitors. *ELife*, **2018**, 7,	8.9	41
68	Discovery of phenylalanine derivatives as potent HIV-1 capsid inhibitors from click chemistry-based compound library. *European Journal of Medicinal Chemistry*, **2018**, 158, 478-492	6.8	36
67	Optimization of N-Substituted Oseltamivir Derivatives as Potent Inhibitors of Group-1 and -2 Influenza A Neuraminidases, Including a Drug-Resistant Variant. *Journal of Medicinal Chemistry*, **2018**, 61, 6379-6397	8.3	32
66	Inhibitors of Influenza Virus Polymerase Acidic (PA) Endonuclease: Contemporary Developments and Perspectives. *Journal of Medicinal Chemistry*, **2017**, 60, 3533-3551	8.3	40
65	Discovery of uracil-bearing DAPYs derivatives as novel HIV-1 NNRTIs via crystallographic overlay-based molecular hybridization. *European Journal of Medicinal Chemistry*, **2017**, 130, 209-222	6.8	17
64	Novel fused pyrimidine and isoquinoline derivatives as potent HIV-1 NNRTIs: a patent evaluation of WO2016105532A1, WO2016105534A1 and WO2016105564A1. *Expert Opinion on Therapeutic Patents*, **2017**, 27, 383-391	6.8	16
63	Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants. *Journal of Medicinal Chemistry*, **2017**, 60, 4424-4443	8.3	65
62	Discovery of novel DAPY-IAS hybrid derivatives as potential HIV-1 inhibitors using molecular hybridization based on crystallographic overlays. *Bioorganic and Medicinal Chemistry*, **2017**, 25, 4397-4406	3.4	16
61	Discovery of Thiophene[3,2-]pyrimidine Derivatives as Potent HIV-1 NNRTIs Targeting the Tolerant Region I of NNIBP. *ACS Medicinal Chemistry Letters*, **2017**, 8, 1188-1193	4.3	21
60	1-Hydroxypyrido[2,3-d]pyrimidin-2(1H)-ones as novel selective HIV integrase inhibitors obtained via privileged substructure-based compound libraries. *Bioorganic and Medicinal Chemistry*, **2017**, 25, 5779-5789	3.4	12
59	Identification of spirocyclic or phosphate substituted quinolizine derivatives as novel HIV-1 integrase inhibitors: a patent evaluation of WO2016094197A1, WO2016094198A1 and WO2016154527A1. *Expert Opinion on Therapeutic Patents*, **2017**, 27, 1277-1286	6.8	5
58	Novel diaryltriazines with a picolinonitrile moiety as potent HIV-1 RT inhibitors: a patent evaluation of WO2016059647(A2). *Expert Opinion on Therapeutic Patents*, **2017**, 27, 9-15	6.8	5

57	Discovery of novel piperidine-substituted indolylarylsulfones as potent HIV NNRTIs via structure-guided scaffold morphing and fragment rearrangement. *European Journal of Medicinal Chemistry*, **2017**, 126, 190-201	6.8	15
56	The development of an effective synthetic route of lesinurad (RDEA594). *Chemistry Central Journal*, **2017**, 11, 86		8
55	An improved synthesis approach of the HIV-1 inhibitor RDEA427, a pyrrolo[2,3-d]pyrimidine derivative. *Arkivoc*, **2017**, 2016, 45-51	0.9	3
54	Medicinal Chemistry Insights into Novel HDAC Inhibitors: An Updated Patent Review (2012-2016). *Recent Patents on Anti-Cancer Drug Discovery*, **2017**, 12, 16-34	2.6	19
53	Discovery of bioactive molecules from CuAAC click-chemistry-based combinatorial libraries. *Drug Discovery Today*, **2016**, 21, 118-132	8.8	101
52	Design, Synthesis, and Evaluation of Thiophene[3,2-d]pyrimidine Derivatives as HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Significantly Improved Drug Resistance Profiles. *Journal of Medicinal Chemistry*, **2016**, 59, 7991-8007	8.3	84
51	Discovery of novel anti-HIV agents via Cu(I)-catalyzed azide-alkyne cycloaddition (CuAAC) click chemistry-based approach. *Expert Opinion on Drug Discovery*, **2016**, 11, 857-71	6.2	26
50	Design, synthesis and evaluation of novel HIV-1 NNRTIs with dual structural conformations targeting the entrance channel of the NNRTI binding pocket. *European Journal of Medicinal Chemistry*, **2016**, 115, 53-62	6.8	16
49	Novel diarylpyrimidines and diaryltriazines as potent HIV-1 NNRTIs with dramatically improved solubility: a patent evaluation of US20140378443A1. *Expert Opinion on Therapeutic Patents*, **2016**, 26, 281-9	6.8	19
48	Design, synthesis and anti-HIV evaluation of novel diarylpyridine derivatives targeting the entrance channel of NNRTI binding pocket. *European Journal of Medicinal Chemistry*, **2016**, 109, 294-304	6.8	26
47	Identification of SNAIL1 Peptide-Based Irreversible Lysine-Specific Demethylase 1-Selective Inactivators. *Journal of Medicinal Chemistry*, **2016**, 59, 1531-44	8.3	21
46	Anti-HIV Drug Discovery and Development: Current Innovations and Future Trends. *Journal of Medicinal Chemistry*, **2016**, 59, 2849-78	8.3	199
45	Structural optimization of pyridine-type DAPY derivatives to exploit the tolerant regions of the NNRTI binding pocket. *European Journal of Medicinal Chemistry*, **2016**, 121, 352-363	6.8	20
44	Arylazolyl(azinyl)thioacetanilides. Part 20: Discovery of novel purinylthioacetanilides derivatives as potent HIV-1 NNRTIs via a structure-based bioisosterism approach. *Bioorganic and Medicinal Chemistry*, **2016**, 24, 4424-4433	3.4	7
43	Strategies for the Discovery of Target-Specific or Isoform-Selective Modulators. *Journal of Medicinal Chemistry*, **2015**, 58, 7611-33	8.3	34
42	Novel fluorine-containing DAPY derivatives as potent HIV-1 NNRTIs: a patent evaluation of WO2014072419. *Expert Opinion on Therapeutic Patents*, **2015**, 25, 1477-86	6.8	5
41	Fragment-based approaches to anti-HIV drug discovery: state of the art and future opportunities. *Expert Opinion on Drug Discovery*, **2015**, 10, 1271-81	6.2	6
40	Design, Synthesis, and Anti-HIV Evaluation of Novel Triazine Derivatives Targeting the Entrance Channel of the NNRTI Binding Pocket. *Chemical Biology and Drug Design*, **2015**, 86, 122-8	2.9	13

39	8-Hydroxyquinoline: a privileged structure with a broad-ranging pharmacological potential. *MedChemComm*, **2015**, 6, 61-74	5	132
38	Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 4: design, synthesis and biological evaluation of novel imidazo[1,2-a]pyrazines. *European Journal of Medicinal Chemistry*, **2015**, 93, 330-7	6.8	37
37	Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches. *European Journal of Medicinal Chemistry*, **2015**, 92, 754-65	6.8	69
36	Synthesis and Preliminary Antiviral Activities of Piperidine-substituted Purines against HIV and Influenza A/H1N1 Infections. *Chemical Biology and Drug Design*, **2015**, 86, 568-77	2.9	14
35	Design, Synthesis, and Biological Evaluation of Novel 4-Aminopiperidinyl-linked 3,5-Disubstituted-1,2,6-thiadiazine-1,1-dione Derivatives as HIV-1 NNRTIs. *Chemical Biology and Drug Design*, **2015**, 86, 107-13	2.9	3
34	Fused heterocyclic compounds bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 1: design, synthesis and biological evaluation of novel 5,7-disubstituted pyrazolo[1,5-a]pyrimidine derivatives. *Bioorganic and Medicinal Chemistry*, **2014**, 22, 2052-9	3.4	55
33	"Old Dogs with New Tricks": exploiting alternative mechanisms of action and new drug design strategies for clinically validated HIV targets. *Molecular BioSystems*, **2014**, 10, 1998-2022		24
32	Design, synthesis and preliminary SAR studies of novel N-arylmethyl substituted piperidine-linked aniline derivatives as potent HIV-1 NNRTIs. *Bioorganic and Medicinal Chemistry*, **2014**, 22, 633-42	3.4	20
31	Recent advances in the structure-based rational design of TNKSIs. *Molecular BioSystems*, **2014**, 10, 2783-99		18
30	Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 2: discovery of novel [1,2,4]Triazolo[1,5-a]pyrimidines using a structure-guided core-refining approach. *European Journal of Medicinal Chemistry*, **2014**, 85, 293-303	6.8	44
29	Discovery of small molecular inhibitors targeting HIV-1 gp120-CD4 interaction drived from BMS-378806. *European Journal of Medicinal Chemistry*, **2014**, 86, 481-90	6.8	20
28	Identification of novel SIRT2-selective inhibitors using a click chemistry approach. *Bioorganic and Medicinal Chemistry Letters*, **2014**, 24, 1871-4	2.9	29
27	Arylazolyl(azinyl)thioacetanilides. Part 16: Structure-based bioisosterism design, synthesis and biological evaluation of novel pyrimidinylthioacetanilides as potent HIV-1 inhibitors. *Bioorganic and Medicinal Chemistry*, **2014**, 22, 5290-7	3.4	9
26	Design, synthesis and anti-HIV evaluation of novel diarylnicotinamide derivatives (DANAs) targeting the entrance channel of the NNRTI binding pocket through structure-guided molecular hybridization. *European Journal of Medicinal Chemistry*, **2014**, 87, 52-62	6.8	31
25	Discovery and characterization of novel imidazopyridine derivative CHEQ-2 as a potent CDC25 inhibitor and promising anticancer drug candidate. *European Journal of Medicinal Chemistry*, **2014**, 82, 293-307	6.8	29
24	Conformational restriction: an effective tactic in Follow-on Rbased drug discovery. *Future Medicinal Chemistry*, **2014**, 6, 885-901	4.1	104
23	Novel HIV-1 non-nucleoside reverse transcriptase inhibitors: a patent review (2011-2014). *Expert Opinion on Therapeutic Patents*, **2014**, 24, 1199-227	6.8	43
22	Downregulation of Ca2+-activated Cl- channel TMEM16A by the inhibition of histone deacetylase in TMEM16A-expressing cancer cells. *Journal of Pharmacology and Experimental Therapeutics*, **2014**, 351, 510-8	4.7	33

21	Recent advances in the discovery and development of novel HIV-1 NNRTI platforms (Part II): 2009-2013 update. *Current Medicinal Chemistry*, **2014**, 21, 329-55	4.3	41
20	Recent progress in the research of small molecule HIV-1 RNase H inhibitors. *Current Medicinal Chemistry*, **2014**, 21, 1956-67	4.3	30
19	"Old friends in new guise": exploiting privileged structures for scaffold re-evolution/refining. *Combinatorial Chemistry and High Throughput Screening*, **2014**, 17, 536-53	1.3	50
18	HIV-1 NNRTIs: structural diversity, pharmacophore similarity, and implications for drug design. *Medicinal Research Reviews*, **2013**, 33 Suppl 1, E1-72	14.4	147
17	Privileged Scaffolds or Promiscuous Binders: A Glance of Pyrrolo[2,1-f][1,2,4]triazines and Related Bridgehead Nitrogen Heterocycles in Medicinal Chemistry. *Current Pharmaceutical Design*, **2013**, 19, 1528-1548	3.3	4
16	Multivalent Agents: A Novel Concept and Preliminary Practice in Anti-HIV Drug Discovery. *Current Medicinal Chemistry*, **2013**, 20, 815-832	4.3	20
15	Identification of highly selective and potent histone deacetylase 3 inhibitors using click chemistry-based combinatorial fragment assembly. *PLoS ONE*, **2013**, 8, e68669	3.7	62
14	Privileged Scaffolds or Promiscuous Binders: A Glance of Pyrrolo[2,1-f][1,2,4]triazines and Related Bridgehead Nitrogen Heterocycles in Medicinal Chemistry. *Current Pharmaceutical Design*, **2013**, 19, 1528-1548	3.3	23
13	Heterocycle-thioacetic acid motif: a privileged molecular scaffold with potent, broad-ranging pharmacological activities. *Current Pharmaceutical Design*, **2013**, 19, 7141-54	3.3	31
12	Privileged scaffolds or promiscuous binders: a glance of pyrrolo[2,1-f][1,2,4]triazines and related bridgehead nitrogen heterocycles in medicinal chemistry. *Current Pharmaceutical Design*, **2013**, 19, 1528-48	3.3	31
11	Design, synthesis, anti-HIV evaluation and molecular modeling of piperidine-linked amino-triazine derivatives as potent non-nucleoside reverse transcriptase inhibitors. *Bioorganic and Medicinal Chemistry*, **2012**, 20, 3856-64	3.4	56
10	Arylazolyl(azinyl)thioacetanilides. Part 10: design, synthesis and biological evaluation of novel substituted imidazopyridinylthioacetanilides as potent HIV-1 inhibitors. *Bioorganic and Medicinal Chemistry*, **2012**, 20, 5527-36	3.4	12
9	Strategies for the design of HIV-1 non-nucleoside reverse transcriptase inhibitors: lessons from the development of seven representative paradigms. *Journal of Medicinal Chemistry*, **2012**, 55, 3595-613	8.3	107
8	The development of HEPT-type HIV non-nucleoside reverse transcriptase inhibitors and its implications for DABO family. *Current Pharmaceutical Design*, **2012**, 18, 4165-86	3.3	14
7	Novel HIV-1 non-nucleoside reverse transcriptase inhibitors: a patent review (2005 - 2010). *Expert Opinion on Therapeutic Patents*, **2011**, 21, 717-96	6.8	44
6	Recent advances in DAPYs and related analogues as HIV-1 NNRTIs. *Current Medicinal Chemistry*, **2011**, 18, 359-76	4.3	86
5	Recent advances in the discovery and development of novel HIV-1 NNRTI platforms: 2006-2008 update. *Current Medicinal Chemistry*, **2009**, 16, 2876-89	4.3	47
4	Design strategies of novel NNRTIs to overcome drug resistance. *Current Medicinal Chemistry*, **2009**, 16, 3903-17	4.3	83

3	Designed multiple ligands: an emerging anti-HIV drug discovery paradigm. *Current Pharmaceutical Design*, **2009**, 15, 1893-917	3.3	57
2	Novel 1,2,3-thiadiazole derivatives as HIV-1 NNRTIs with improved potency: Synthesis and preliminary SAR studies. *Bioorganic and Medicinal Chemistry*, **2009**, 17, 5920-7	3.4	71
1	Recent advances in the research of HIV-1 RNase H inhibitors. *Mini-Reviews in Medicinal Chemistry*, **2008**, 8, 1243-51	3.2	16